"10.1371_journal.pone.0070201","plos one","2013-07-26T00:00:00Z","José R Santos; José A Muñoz-Moreno; José Moltó; Anna Prats; Adrià Curran; Pere Domingo; Josep M Llibre; Daniel R McClernon; Isabel Bravo; Jaume Canet; Victoria Watson; David Back; Bonaventura Clotet","Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Infectious Diseases Department, Hospital Vall dHebron, Barcelona, Spain; Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; bioMONTR, Research Triangle Park, North Carolina, United States of America; Department of Anesthesiology and Postoperative Care Unit, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom; Bioanalytical Facility, Royal Liverpool Hospital Trust, Liverpool, United Kingdom; IrsiCaixa Foundation, Barcelona, Spain","Conceived and designed the experiments: JR-S JM-M JM. Performed the experiments: JR-S JMM JM AP DRM JC VW DB. Analyzed the data: JR-S JM-M JM. Contributed reagents/materials/analysis tools: IB AC PD. Wrote the paper: JR-S JM-M JM AC PD JML DRM JC VW DB BC.","José R. Santos has received research funding, consultancy fees, and lecture sponsorships from and has served on advisory boards for Abbott, Boehringer Ingelheim, Gilead Sciences, Glaxo Smith-Kline, Janssen-Cilag, Bristol-Myers Squibb, ViiV Healthcare, and Pfizer. Jose A. Muñoz-Moreno has received research funding, consultancy fees, and lecture sponsorships from and has served on advisory boards for Abbott, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead Sciences, Glaxo Smith-Kline, Merck Sharp & Dohme, and ViiV Healthcare. José Moltó has received research funding, consultancy fees, and lecture sponsorships from and has served on advisory boards for Abbott, Boehringer Ingelheim, Gilead Sciences, Glaxo Smith-Kline, Janssen-Cilag, Bristol-Myers Squibb, ViiV Healthcare, and Pfizer. Adrià Curran has received research funding, consultancy fees, and lecture sponsorships from and has served on advisory boards for Abbott, Boehringer Ingelheim, Gilead Sciences, Glaxo Smith-Kline, Janssen-Cilag, Bristol-Myers Squibb, ViiV Healthcare, and Pfizer. Pere Domingo has received research funding, consultancy fees, and lecture sponsorships from and has served on advisory boards for Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Glaxo SmithKline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Roche, Schering-Plough, and ViiV Healthcare. Josep M Llibre has received research funding, consultancy fees, and lecture sponsorships from and has served on advisory boards for Abbott, Boehringer Ingelheim, Gilead Sciences, Glaxo Smith-Kline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, and ViiV Healthcare. Daniel R. McClernon has received consultancy fees, research funding and has served on advisory boards Abbott Molecular, DNA Genotek, Glaxo Smith-Kline, Quest Diagnostics, Siemens Healthcare, Vivebio LLC and ViiV Healthcare. David Back has received research funding, consultancy fees and lecture sponsorship from and has served on Advisory Boards for Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme, Vertex and ViiV Healthcare. Bonaventura Clotet has received research funding, consultancy fees, and lecture sponsorships from and has served on advisory boards for Abbott, Boehringer-Ingelheim, Gilead Sciences, Glaxo Smith-Kline, Janssen-Cilag, Merck Sharp & Dohme, Panacos, Pfizer, Roche, and Tibotec. Anna Prats, Victoria Watson, Jaume Canet and Isabel Bravo declare no competing interests. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.",NA,NA,NA,"2013","07","José R Santos","JRS",13,FALSE,3,8,3,11,TRUE,TRUE,FALSE,0,NA,FALSE
